Trial and Protocol Number Pediatric Cancers |
Phase II |
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
NCI-12-C-0098, NCT01502410
Principal Investigator: | Referral Contact: | Brigitte Widemann | Pediatric Oncology | 301-496-7387 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
Phase I/II |
Phase I/II Trial of Mithramycin In Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWS-FLI1 Fusion Transcript
NCI-12-C-0135, NCT01610570
Principal Investigator: | Referral Contact: | Brigitte Widemann | Pediatric Oncology | 301-496-7387 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
Phase I |
A Phase I Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With
Recurrent or Refractory Solid Tumors, Including CNS Tumors
NCI-13-C-0042, NCT01709435
Principal Investigator: | Referral Contact: | Brigitte Widemann | Pediatric Oncology | 301-496-7387 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
NCI-12-C-0138 , NCT01431534
Principal Investigator: | Referral Contact: | Lee J. Helman | Pediatric Oncology | 301-496-4257 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
A Phase I Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
NCI-12-C-0208, NCT01518413
Principal Investigator: | Referral Contact: | Brigitte Widemann | Pediatric Oncology | 301-496-7387 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors
NCI-12-C-0140
Principal Investigator: | Referral Contact: | Lee J. Helman | Pediatric Oncology | 301-496-4257 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
NCI-12-C-0112, NCT01593696
Principal Investigator: | Referral Contact: | Alan S. Wayne | Pediatric Oncology | 301-496-4256 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
NCI-11-C-0073, NCT01287104
Principal Investigator: | Referral Contact: | Kristin Baird | Pediatric Oncology | 301-496-4256 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
Phase I Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
NCI-11-C-0053, NCT01141244
Principal Investigator: | Referral Contact: | Brigitte Widemann | Pediatric Oncology | 301-496-7387 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
NCI-11-C-0047, NCT01259479
Principal Investigator: | Referral Contact: | Brigitte Widemann | Pediatric Oncology | 301-496-7387 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo® (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer
NCI-10-C-0220, NCT01222780
Principal Investigator: | Referral Contact: | Alan S. Wayne | Pediatric Oncology | 301-496-4256 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
NCI-10-C-0178, NCT01182896
Principal Investigator: | Referral Contact: | Brigitte Widemann | Pediatric Oncology | 301-496-7387 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer
NCI-08-C-0007, NCT00556881
Principal Investigator: | Referral Contact: | Melinda Merchant | Pediatric Oncology | 301-443-7955 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
No Phase |
Understanding the Perceived Influence of Childhood Cancer on the Parents’ Marital/Partner Relationship: A Descriptive Study
NCI-12-C-0206, NCT01702922
Principal Investigator: | Referral Contact: | Lori S. Wiener | Pediatric Oncology | 301-451-9148 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults With Chronic Illness and Their Parents
NCI-12-C-0160, NCT01639950
Principal Investigator: | Referral Contact: | Staci M. Peron | Pediatric Oncology | 301-435-3964 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer
NCI-11-C-0132, NCT01324154
Principal Investigator: | Referral Contact: | Lori S. Wiener | Pediatric Oncology | 301-451-9148 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|
A Comprehensive Omics Analysis of Pediatric Oncology Solid Tumors and Establishment of a Repository for Related Biological Studies
NCI-10-C-0086, NCT01109394
Principal Investigator: | Referral Contact: | Javed Khan | Pediatric Oncology | 301-435-2937 | 301-496-4256 1-877-624-4878 (Toll free) | |
|
|